Journal of Biotechnology & Biomaterials
Open Access

Abstract

Catalytic Abs (catAbs) are multivalent im-munoglobulins (Igs) with a capacity to hy-drolyze the antigenic (Ag) substrate. In this sense, proteolytic Abs (Ab-proteases) repre-sents Abs to provide proteolytic effects. Abs against myelin basic protein/ MBP with pro-teolytic activity exhibiting sequence-specific cleavage of MBP is of great value to monitor demyelination whilst in multiple sclerosis. The activity of Ab-proteases was first regis-tered at the subclinical stages, 1-2 years prior to the clinical illness and the activity of the Ab-proteases revealed significant correlation with scales of demyelination and the disabil-ity of the patients as well. So, the activity of Ab-proteases and its dynamics tested would confirm a high subclinical and predictive (translational) value of the tools as applicable for personalized monitoring protocols. Ab-proteases directly affecting remodeling of tissues with multilevel architectonics (for in-stance, myelin) are of tremendous value. By changing sequence specificity one may reach reduction of a density of the negative proteo-lytic effects within the myelin sheath and thus minimizing scales of demyelination. Ab-proteases can be programmed and re-programmed to suit the needs of the body metabolism or could be designed for the de-velopment of new catalysts with no natural counterparts. Further studies are needed to secure artificial or edited Ab-proteases as translational tools of the newest generation to diagnose, to monitor, to control and to treat and rehabilitate multiple sclerosis patients at clinical stages and to prevent the disorder at subclinical stages in persons at risks. Recent Publications 1. Gabibov A A, Paltsev M A and Suchkov S V (2011) Antibody-associated proteol-ysis in surveillance of autoimmune de-myelination: clinical and preclinical is-sues. Future Neurology 6(3):303-305. 2. D Kostyushev, I Tsarev, D Gnatenko, M Paltsev and S Suchkov (2011) Myelin-associated serological targets as applicable to diagnostic tools to be used at the preclinical and transient stages of multiple sclerosis progression. Open J Immunology 1(3):80-86. 3. Gabibov A G, Ponomarenko N A, Tretyak E B, Paltsev M A and Suchkov S V (2006) Catalytic autoantibodies in clinical autoimmunity and modern medicine. Autoimmunity Reviews 2006(5):324-330. 4. Ponomarenko N A, Durova O M, Voro-biev I I, Belogurov A A, Telegin G B, et al. (2005) Catalytic activity of autoantibodies toward myelin basic protein corre-lates with the scores on the multiple scle-rosis expanded disability status scale. Immunol. Lett. 103(1):45-50. 5. Ponomarenko N A, Durova O M, Voro-biev I I, Aleksandrova E S, Telegin G B, et al. (2002) Catalytic antibodies in clini-cal and experimental pathology: human and mouse models. Journal of Immuno-logical Methods 2002(269):197211.

Biography

Sergey Suchkov graduated from Astrakhan State Medical University and awarded with MD, then in 1985 maintained his PhD at the I M Sechenov Moscow Medical Academy and in 2001, he maintained his Doctorship Degree at the Nat Inst of Immunology, Russia. From 1987 through 1989, he was a senior Researcher, Koltzov Inst of Developmental Biology. From 1989 through 1995, he was a Head of the Lab of Clinical Immunology, Helmholtz Eye research Institute in Moscow. From 1995 through 2004, he was a Chair of the Dept. for Clinical Immunology, Moscow Clinical Research Institute. He has been trained at: NIH; Wills Eye Hospital, PA, USA; Univ. of Florida in Gainesville; UCSF, S-F, CA, USA; Johns Hopkins University, Baltimore, MD, USA. He was an Exe Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. At present, he is a Chair, Dept. for Personal-ized and Translational Medicine, I M Sechenov First Moscow State Medical University. He is a member of the New York Academy of Sciences, USA; American Chemical Society (ACS), USA; American Heart Association (AHA), USA; EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU; ARVO (American Association for Research in Vision and Ophthalmology); ISER (International Society for Eye Re-search); PMC (Personalized Medicine Coalition), Washington, USA.
Email:ssuchkov57@gmail.com